Manatuck Hill Partners’s DiaMedica Therapeutics DMAC Stock Holding History

Manatuck Hill Partners’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-144,800	Closed	-$540K	–	124
2021 Q4	$540K	Sell	144,800 -128,300	-47%	-$504K	0.2%	79
2021 Q3	$1.09M	Sell	273,100 -297,400	-52%	-$1.14M	0.38%	56
2021 Q2	$2.54M	Hold	570,500	–	–	0.77%	41
2021 Q1	$5.22M	Sell	570,500 -1,000	-0.2%	-$9.34K	1.77%	20
2020 Q4	$5.79M	Hold	571,500	–	–	2.32%	11
2020 Q3	$2.42M	Buy	571,500 +220,400	+63%	+$1.17M	1.11%	28
2020 Q2	$2.43M	Hold	351,100	–	–	1.4%	23
2020 Q1	$983K	Buy	351,100 +78,700	+29%	+$325K	0.9%	32
2019 Q4	$1.32M	Hold	272,400	–	–	0.69%	44
2019 Q3	$564K	Buy	272,400 +5,100	+2%	+$16.5K	0.31%	61
2019 Q2	$1.33M	Buy	267,300 +115,800	+76%	+$400K	0.62%	40
2019 Q1	$688K	Sell	151,500 -48,500	-24%	-$175K	0.33%	67
2018 Q4	$582K	Buy	+200,000	New	+$628K	0.3%	64

Other funds holding DMAC

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Manatuck Hill Partners's DMAC Position: Q1 2022 in Review

Manatuck Hill Partners sold out of DiaMedica Therapeutics (DMAC) in Q1 2022, closing a stake of 144,800 shares — an estimated $540K sold.

Manatuck Hill Partners first reported a position in DMAC in Q4 2018 and held it in 13 quarters. The position peaked at $5.79M in Q4 2020. 34 funds tracked by Wall St. Rank hold DMAC as of Q1 2022.

Manatuck Hill Partners reported no remaining DiaMedica Therapeutics position as of Q1 2022 after selling out during the quarter.
Manatuck Hill Partners sold 144,800 DiaMedica Therapeutics shares in Q1 2022, an estimated $540K.
Manatuck Hill Partners first reported a position in DiaMedica Therapeutics in Q4 2018 and held it in 13 quarters.
Manatuck Hill Partners's DiaMedica Therapeutics position peaked at $5.79M in Q4 2020.
34 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2022.

Based on Manatuck Hill Partners's 13F filing for Q1 2022, filed 16 May 2022.